ELECTROMED INC (ELMD)
Health Care · respiratory medical devices · NYSE American
Electromed is a medical technology company that helps patients breathe easier by providing innovative, self-administered High Frequency Chest Wall Oscillation (HFCWO) airway clearance therapy.
What ELECTROMED INC does
Electromed, Inc. develops, manufactures, and markets innovative airway clearance products using High Frequency Chest Wall Oscillation (HFCWO) technology. The company primarily utilizes a direct-to-patient model to provide the SmartVest Airway Clearance System for patients suffering from bronchiectasis, cystic fibrosis, and various neuromuscular conditions. Additionally, its products are sold into the acute care hospital setting for patients with post-surgical or respiratory complications.
Recent developments
The company reported record fiscal 2026 financial results, including 15.3% annual revenue growth and 43.7% growth in operating income. Electromed marked its 15th consecutive quarter of year-over-year revenue and profit growth as of the fiscal 2026 fourth quarter.
From ELECTROMED INC's filing of 2026-08-25.
Themes: pulmonary care, airway clearance therapy, home health care, respiratory health management, bronchiectasis market development
Fundamentals
- Price$27.32 as of 2026-10-21 close
- Market cap$229M as of 2026-08-19 (share count; price 2026-10-21)
- 1-year return+10.3% 2025-10-21 close $24.78 → 2026-10-21 close $27.32
- P/E21.02 as of 2026-10-21
- Net margin+15.3% FY2026, SEC XBRL
- Gross margin+78.5% FY2026, SEC XBRL
- ROE+20.9% FY2026, SEC XBRL
- ROICn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)+15.3% FY2026, SEC XBRL
- Revenue CAGR (3y)+15.4% SEC XBRL
- Beta0.81 as of 2026-09-03
- Last reported earnings2026-08-25 SEC EDGAR Form 8-K (Item 2.02)
How ELMD compares in its sector
- price-to-earnings ratiomiddle range 181 covered Health Care peers, as of 2026-10-21
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- gross margintop 25% 189 covered Health Care peers, as of 2026-09-03
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q4 FY2026 2026-06-30 | $19M† | $15M† | $4M† | $3M† | $0.39† | $3M† | $219000† |
| Q3 FY2026 2026-03-31 | $19M | $15M | $4M | $3M | $0.35 | $3M† | $147000† |
| Q2 FY2026 2025-12-31 | $19M | $15M | $4M | $3M | $0.32 | $3M† | $634000† |
| Q1 FY2026 2025-09-30 | $17M | $13M | $3M | $2M | $0.25 | $169000 | $252000 |
| Q4 FY2025 2025-06-30 | $17M† | $14M† | $3M† | $2M† | $0.26† | $4M† | $145000† |
| Q3 FY2025 2025-03-31 | $16M | $12M | $2M | $2M | $0.21 | $2M† | -$153000† |
| Q2 FY2025 2024-12-31 | $16M | $13M | $3M | $2M | $0.22 | $3M† | $233000† |
| Q1 FY2025 2024-09-30 | $15M | $11M | $2M | $1M | $0.16 | $2M | $37000 |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$20M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How ELECTROMED INC looks technically
ELECTROMED INC (ELMD) is trading 12.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 2 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 14 trading days ago. It is 42.1% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 45% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 12.1% below its 200-day average, the long-term trend line — a long-term downtrend | -12.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $30.68 | $30.68 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $31.22 | $31.22 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 19 calendar days ago — the swings before that are what the structure reading is measured on | 19 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes above 28.95. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 2 trading days ago — a "death cross", a bearish long-term signal | 2 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with sellers in control | 25.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30) | 38.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($27.15 to $28.95) — its "stochastic" reading is 16 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 16.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 23 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $47.38 | $47.38 |
|---|---|---|
| From the 52-week high | it is 42.1% below its 52-week high (its highest price of the past year) | -42.1% |
| Above the 52-week low | it is 19.3% above its 52-week low (its lowest price of the past year) | +19.3% |
| Below the 52-week high | it is 42.1% below its highest point of the past year | 42.1% |
| Since a 20-day breakout | it made a new 20-day high about 14 trading days ago | 14 sessions |
| Since a 55-day breakout | it made a new 55-day low about 25 trading days ago | 25 sessions |
| All-time high | its highest closing price on record is $47.38 (set on 2026-07-14) | $47.38 |
| Given back of the 52-week move | over the past year its closes ranged ($23.15 to $46.31), and it has given back almost all of its rise from last year’s low — 81% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $31.26 to $32.00. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 81.5% |
| From the all-time high | it is 42.1% below its all-time high | -42.1% |
| Nearest price level | it is trading 0.7% above a support level at $27.24 — a price it turned at twice since 2024-12-05, most recently on 2026-01-22. Since 2024-10-21 it has 8 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.7% |
| All-time low | its lowest closing price on record is $0.9015 (set on 2013-09-13) | $0.9015 |
| Above the all-time low | it is 2943.8% above its all-time low | +2,944% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 1st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.9157 between its high and its low — about 3.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.9157 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $27.25 and $28.60 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $27.25 – $27.92 – $28.60 |
| Typical daily range (% of price) | its price moves about 3.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.3% |
| Stretch from the 200-day average | it is trading 4.1 daily ranges below its 200-day average price (12.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 45% of its 30-day average | 0.45× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
4
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a hammer | 4 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 4 sessions ago |
| Since a bullish engulfing | 6 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 6 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Open gap | it gapped 2.0% below the previous close 35 sessions ago and has not traded back through the level it left behind at 29.6 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.0% |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 2.5 percentage points (the stock gained 3.4% while the market gained 1.0%) | +2.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 36.5 percentage points (the stock lost 32.9% while the market gained 3.6%) | -36.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 0.5 percentage points (the stock gained 8.0% while the market gained 8.5%) | -0.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 4.0 percentage points (the stock gained 10.5% while the market gained 14.6%) | -4.0% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: MACD momentum is positive, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 13% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 19.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -12.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 16% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $32.60 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | -15.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-25 (its 10-K), so the typical buyer over that stretch is under water. That average is $28.38 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP. | -3.3% |
Price levels it has turned at before
ELMD last closed at $27.44 on 2026-10-20. Since 2024-10-21 it has turned at 8 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $27.24 | Support | 0.7% below the last close | turned there twice · 2024-12-05 to 2026-01-22 |
| $26.78 | Support | 2.4% below the last close | turned there five times · 2024-12-23 to 2026-04-27 |
| $28.15 | Resistance | 2.6% above the last close | turned there three times · 2025-02-11 to 2026-09-22 |
| $25.76 | Support | 6.1% below the last close | turned there twice · 2025-10-06 to 2026-09-16 |
| $29.79 | Resistance | 8.6% above the last close | turned there twice · 2024-11-13 to 2026-01-08 |
| $30.61 | Resistance | 11.6% above the last close | turned there twice · 2025-12-15 to 2026-02-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes above $28.95.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $13.40 and $23.01 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 13 trading days, since 2026-10-02.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$48.50 range $47.00 – $50.00
Analyst estimates, as of 2026-10-15. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["dependence on reimbursement from private insurance, Medicare, and Medicaid","reliance on a direct sales model and sales representative productivity","intense competition in the airway clearance market"]
What changed in the latest 10-Q
AI-assisted comparison of ELMD's 10-Q filed 2026-05-12 against the prior one filed 2026-02-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing reports financial results for nine months ended March 31, 2026, compared to nine months ended March 31, 2025
- Newer filing includes breakdown of homecare revenue increase attributing $1,959,000 to higher volume and $671,000 to higher net revenues per approval for three months
- Newer filing includes breakdown of homecare revenue increase attributing $5,699,000 to higher volume and $1,290,000 to higher net revenues per approval for nine months
- Newer filing states averaged 57 homecare field sales representatives for three months ended March 31, 2026
- Newer filing adds detail that hospital revenue growth reflects 'increase in sales representatives focused on the hospital market and higher capital and disposal demand'
- Newer filing provides gross profit percentages of 78.8% and 78.5% for three and nine months ended March 31, 2026
- Removed:
- Older filing reports financial results for six months ended December 31, 2025, compared to six months ended December 31, 2024
- Older filing states averaged 58 homecare field sales representatives for three months ended December 31, 2025
- Older filing includes explanation that hospital revenue decrease in three months was 'due to fewer capital equipment orders as hospital capital revenue is a long-cycle sale'
- Older filing provides gross profit percentages of 78.4% and 78.3% for three and six months ended December 31, 2025
- Reworded:
- Change from 'that require external chest manipulation' to 'that require external chest manipulation' - no material change (identical wording in both texts)
- Change from 'There were no material changes' (older) to 'There have been no material changes' (newer) in Critical Accounting Estimates section
- Older filing states homecare increases were 'primarily due to an increase in direct sales representatives and higher net revenues per sales representative' versus newer filing providing specific dollar and volume attributions
- Notes:
- The two filings cover different reporting periods (nine months ended March 31, 2026 in newer versus six months ended December 31, 2025 in older), making direct financial comparison limited to overlapping narrative content
- The newer filing text appears truncated at the SG&A expenses section, limiting assessment of completeness of differences in Operating Expenses section
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 6 days since 2026-10-16 have not been checked yet.
- Last 180 days · read to 2026-10-160 buys · 9 sells ($2M) — 3 selling insiders
Most recent open-market transaction: 2026-06-08. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ELMD's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ELMD as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 764,075
- Reported value $32,320,378
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ELMD's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ELMD had 204,336 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
ELMD had 2.44% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2 days to cover at the same settlement.
- Reported short interest (shares) 204,336
- Short interest (% of shares outstanding) 2.44%
- Prior settlement (shares) 206,831
- Reported change -1.21%
- Days to cover (reported) 2
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Hill-Rom (Baxter International BAX)
- Philips Healthcare (PHG)
- ResMed (RMD)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ELMD vs…
Frequently asked questions
What does ELECTROMED INC (ELMD) do?
Electromed, Inc. develops, manufactures, and markets innovative airway clearance products using High Frequency Chest Wall Oscillation (HFCWO) technology. The company primarily utilizes a direct-to-patient model to provide the SmartVest Airway Clearance System for patients suffering from bronchiectasis, cystic fibrosis, and various neuromuscular conditions. Additionally, its products are sold into the acute care hospital setting for patients with post-surgical or respiratory complications.
What sector is ELECTROMED INC (ELMD) in?
ELECTROMED INC (ELMD) is classified in the Health Care sector. Its industry is respiratory medical devices. It trades on NYSE American.
Who are ELECTROMED INC's (ELMD) competitors?
Notable peers of ELECTROMED INC (ELMD) include Hill-Rom (Baxter International BAX), Philips Healthcare and ResMed. This peer set is informational only — not financial advice.
Is ELECTROMED INC (ELMD) overbought or oversold right now?
ELECTROMED INC (ELMD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 39, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ELMD come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.